Navigation Links
Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting
Date:5/21/2009

REDWOOD CITY, Calif., May 21 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from three studies at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2009, at the Orange County Convention Center in Orlando, Florida. The company currently markets the widely-adopted Oncotype DX(R) breast cancer test, which is clinically validated to predict the likelihood of recurrence and chemotherapy benefit in early-stage breast cancer patients, and plans to launch a test for colon cancer in early 2010 based on positive results from the QUASAR validation study being presented at ASCO.

    Presentation details are as follows:

    Colon Cancer
        -- Saturday, May 30, 2009, 3 p.m. ET
           Abstract # 4000
           Oral presentation: "A quantitative multi-gene RT-PCR assay for
           prediction of recurrence in stage II colon cancer:  Selection of
           the genes in 4 large studies and results of the independent,
           prospectively-designed QUASAR validation study" Presenter: David
           Kerr, M.D., DSc, professor of cancer medicine at the University of
           Oxford Location: Level 2, West Hall D2

    In addition, an archived webcast of the advance presscast highlighting the
    QUASAR colon cancer validation study is available on ASCO's Web site at
    www.asco.org.

    Breast Cancer
        -- Sunday, May 31, 2009, 4:30 p.m. ET
           Abstract # 500
           Oral presentation: "Genotypic characterization of phenotypically
           defined triple-negative breast cancer"
           Presenter: Joseph A. Sparano, M.D., professor of medicine and
           women's health at Albert Einstein College of Medicine and director
           of the Breast Evaluation Center of Montefiore-Einstein Cancer
           Center in the Bronx, New York
           Location: Level 2, West Hall D2

        -- Monday, June 1, 2009, 1-5:00 p.m. ET
           Abstract # 549
           Poster presentation: "Molecular characterization of male breast
           cancer by standardized quantitative RT-PCR analysis: First large
           genomic study of 347 male breast cancers compared to 82,434 female
           breast cancers"
           Presenter: Steve Shak, M.D., chief medical officer, Genomic Health
           Poster board: A17
           Location: Level 2, West Hall C

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX(R) breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the applicability of clinical study results to actual outcomes and the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology: